- Cancer Biology & Biomarkers
- Chromatography & Mass Spectrometry
- Contract Research, Clinical Trials and Outsourcing
- Drug Discovery
- Drug Targets
- Flow Cytometry
- Informatics & Lab Automation
- Ingredients, Excipients and Dosages
- Microbiology & RMMs
- NIR, PAT & QbD
- Raman Spectroscopy
- Screening, Assays & High-Content Analysis
- Thermal Processing
- Events & Workshops
New study with Victoza showed improvements in blood glucose control in adults with type 2 diabetes who fasted during Ramadan
8 June 2015 • Author: Victoria White
New findings showed that adults with type 2 diabetes treated with Novo Nordisk‘s Victoza® (liraglutide), in combination with metformin, experienced similar improvements in blood glucose control while fasting during Ramadan compared with sulfonylurea (SU) plus metformin.
People treated with Victoza also demonstrated significantly better weight loss and fewer confirmed hypoglycaemic episodes compared with those treated with sulfonylurea during Ramadan. Findings from the LIRA-Ramadan™ study were presented at the 75th Annual Scientific Sessions of the American Diabetes Association (ADA).
Greater weight loss was observed in people treated with Victoza
The 33-week, open-label, randomised study showed that Victoza sustained blood glucose control during four weeks of Ramadan, with similar reductions in fructosamine levels compared with sulfonylurea. Testing fructosamine allows the effectiveness of diabetes treatment to be reliably evaluated after a couple of weeks. During Ramadan, patients treated with Victoza experienced fewer confirmed hypoglycaemic episodes compared with people treated with sulfonylurea, even though the Victoza group had lower fructosamine concentration at the start of Ramadan. In addition, greater weight loss was observed in people treated with Victoza during Ramadan vs. sulfonylurea.
“Fasting during Ramadan presents unique medical challenges for people living with type 2 diabetes and their healthcare providers,” said Dr Sami Azar, Professor of Medicine at the American University of Beirut Medical Centre, Beirut, Lebanon and principal investigator of the LIRA-Ramadan™ trial. “Prolonged fasting, often followed by large nighttime meals, can affect blood glucose levels and result in severe hypoglycaemia and hyperglycaemia. To help minimise these risks, physicians and people with type 2 diabetes should consider evaluating and discussing diabetes management plans in advance of Ramadan.”
More than 50 million Muslims worldwide with diabetes fast during Ramadan. Muslims with type 2 diabetes who fast have an estimated 7.5–fold increased risk of severe hypoglycaemia and a five-fold increased risk of severe hyperglycaemia (requiring hospitalisation) during Ramadan.
ABB Analytical Measurement ACD/Labs ADInstruments Ltd Advanced Analytical Technologies GmbH Analytik Jena AG Astell Scientific Ltd B&W Tek Bachem AG Bibby Scientific Limited Bio-Rad Laboratories BioNavis Ltd Biopharma Group Black Swan Analysis Limited Butterworth Laboratories Ltd CAPSUGEL NV Charles Ischi AG | Kraemer Elektronik Cherwell Laboratories CI Precision Cobalt Light Systems Coulter Partners CPC Biotech srl Dassault Systèmes BIOVIA DiscoverX Edinburgh Instruments Enterprise System Partners (ESP) Eurofins BioPharma Product Testing EUROGENTEC F.P.S. Food and Pharma Systems Srl GE Analytical Instruments IDBS JEOL Europe L.B. Bohle Maschinen + Verfahren GmbH Lab M Ltd. LabWare Linkam Scientific Instruments Limited MA Business Metrohm Molins Technologies Multicore Dynamics Ltd Nanosurf New England Biolabs, Inc. Ocean Optics Panasonic Biomedical Sales Europe B.V. PerkinElmer Inc ReAgent Russell Finex Limited Source BioScience Takara Clontech Tornado Spectral Systems Tuttnauer Viavi Solutions, Inc Watson-Marlow Fluid Technology Group Wickham Laboratories Limited Xylem Analytics YMC Europe GmbH Yusen Logistics